Metavia Inc (MTVA) Stock Price, Quote & News

Company Profile

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomod...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 702 9600

Website: www.metaviatx.com

Address:

545 Concord Avenue, Suite 210, Cambridge, United States

TraderRapp Sep. 9 at 3:16 PM

$MTVA when is R/S?

1 · Reply

G101SPM Sep. 4 at 6:51 PM

#SHOWTIME H.C. Wainwright Global Investment Conference (September 5-9) Scheduled to appear: $ANCN, $CGEN, $INO, $MTVA, $MAG

0 · Reply

JarvisFlow Sep. 4 at 11:30 AM

HC Wainwright & Co. has updated their rating for MetaVia ( $MTVA ) to Buy with a price target of 12.

0 · Reply

Basko151 Sep. 4 at 12:33 AM

$MTVA buy buy buy…all I have don for 3 years now…😩

0 · Reply

Mike93 Sep. 3 at 2:48 PM

$MTVA 15k watchers but no one posting hmm, I feel like arriving early at a party

1 · Reply

Mike93 Sep. 3 at 1:07 PM

$MTVA getting ready

0 · Reply

Mike93 Sep. 2 at 2:30 PM

$MTVA loaded here, waiting for a pump

0 · Reply

MGeronimo Aug. 27 at 9:54 PM

$MTVA ADDING AT .63

0 · Reply

Basko151 Aug. 26 at 1:16 AM

$MTVA Just keep buying…glutton

0 · Reply

BioTerror Aug. 25 at 8:38 PM

$MTVA loaded.

0 · Reply

MetaVia to Present at Upcoming Investor and Industry Conferences

Aug 7, 2025, 8:31 AM EDT - 5 weeks ago

MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 8:31 AM EDT - 5 weeks ago

MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

Aug 4, 2025, 8:31 AM EDT - 5 weeks ago

MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241

Jul 9, 2025, 8:31 AM EDT - 2 months ago

MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

Jun 21, 2025, 9:00 AM EDT - 2 months ago

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session

Jun 10, 2025, 8:31 AM EDT - 3 months ago

MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th

Jun 4, 2025, 8:31 AM EDT - 3 months ago

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions

May 14, 2025, 4:05 PM EDT - 4 months ago

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 9, 2025, 8:01 AM EDT - 4 months ago

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

May 7, 2025, 2:00 AM EDT - 4 months ago

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

Apr 23, 2025, 8:31 AM EDT - 5 months ago

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

Apr 22, 2025, 8:31 AM EDT - 5 months ago

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

Apr 15, 2025, 7:01 AM EDT - 5 months ago

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

Mar 20, 2025, 7:31 AM EDT - 6 months ago

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Jan 10, 2025, 8:05 AM EST - 8 months ago

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

Nov 18, 2024, 8:01 AM EST - 10 months ago

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

Nov 13, 2024, 8:01 AM EST - 10 months ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

Nov 7, 2024, 8:01 AM EST - 11 months ago

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 4, 2024, 8:01 AM EST - 11 months ago

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Oct 1, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

Sep 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Sep 3, 2024, 8:01 AM EDT - 1 year ago

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Aug 6, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

Jul 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

Jul 11, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July

Jun 26, 2024, 9:06 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Jun 25, 2024, 5:08 PM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 24, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 22, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

May 22, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone

May 9, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

Apr 17, 2024, 8:05 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Apr 1, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Mar 28, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

Mar 13, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Mar 4, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

Feb 29, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Feb 12, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference

Feb 1, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

Jan 18, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Jan 9, 2024, 8:30 AM EST - 1 year ago

NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement

Jan 2, 2024, 8:01 AM EST - 1 year ago

NeuroBo to Participate in Industry and Investor Conferences in January

Dec 28, 2023, 8:45 AM EST - 1 year ago

NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

Dec 19, 2023, 8:43 AM EST - 1 year ago

NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Dec 1, 2023, 8:31 AM EST - 1 year ago

NeuroBo to Participate in Investor Conferences in December

Nov 13, 2023, 4:05 PM EST - 1 year ago

NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

TraderRapp Sep. 9 at 3:16 PM

$MTVA when is R/S?

1 · Reply

G101SPM Sep. 4 at 6:51 PM

#SHOWTIME H.C. Wainwright Global Investment Conference (September 5-9) Scheduled to appear: $ANCN, $CGEN, $INO, $MTVA, $MAG

0 · Reply

JarvisFlow Sep. 4 at 11:30 AM

HC Wainwright & Co. has updated their rating for MetaVia ( $MTVA ) to Buy with a price target of 12.

0 · Reply

Basko151 Sep. 4 at 12:33 AM

$MTVA buy buy buy…all I have don for 3 years now…😩

0 · Reply

Mike93 Sep. 3 at 2:48 PM

$MTVA 15k watchers but no one posting hmm, I feel like arriving early at a party

1 · Reply

Mike93 Sep. 3 at 1:07 PM

$MTVA getting ready

0 · Reply

Mike93 Sep. 2 at 2:30 PM

$MTVA loaded here, waiting for a pump

0 · Reply

MGeronimo Aug. 27 at 9:54 PM

$MTVA ADDING AT .63

0 · Reply

Basko151 Aug. 26 at 1:16 AM

$MTVA Just keep buying…glutton

0 · Reply

BioTerror Aug. 25 at 8:38 PM

$MTVA loaded.

0 · Reply

Paulfrench Aug. 22 at 7:16 AM

$MTVA For a Graphic point of view, In my opinion, we are missing a small tetracement at $0.60 to consider a significant increase.

1 · Reply

ZacksSCR Aug. 13 at 7:31 PM

$MTVA: Results from 8-week Study of 48 mg DA-1726 Expected Before End of 2025… https://buff.ly/OTCGp14

1 · Reply

Kertzi Aug. 11 at 5:22 AM

$MTVA ⚠️ Why Success Is Highly Unlikely for MetaVia 🧪 1. The Pipeline Lacks Conviction - DA-1241: Mediocre Phase 2a results, no breakthrough efficacy - DA-1726: Clearly outclassed by competitors like Zepbound and Wegovy - No new drug candidates—just AI-driven indication fishing 💸 2. Funding Is Weak and Unstable - Armistice Capital involved—a Toxic lender known for dumping shares and crushing stock prices - No strategic funding from Dong-A ST, despite being a major shareholder - Nasdaq delisting risk due to sub-$1 share price 🧑‍💼 3. Leadership Inspires Little Confidence - No prior FDA approvals or successful drug launches - Minimal insider ownership—no skin in the game - Frequent executive turnover and reactive, not visionary, strategy... 📉 4. Ruthless Market Dynamics - Competing against industry giants: Eli Lilly, Novo Nordisk, Pfizer - MetaVia offers no clear differentiator - Trading as a penny stock—off the radar for institutional investor

0 · Reply

prismmarketview Aug. 4 at 4:17 PM

$MTVA is partnering with AI drug discovery firm Syntekabio to unlock new indications for its oral GPR119 agonist. Following strong Phase 2a results in MASH, MetaVia is now expanding the therapeutic potential of DA-1241 across liver and metabolic diseases using predictive AI modeling. https://prismmarketview.com/metavia-accelerates-metabolic-disease-pipeline-with-syntekabio-ai-collaboration/

0 · Reply

Kertzi Aug. 4 at 2:51 PM

$MTVA Korean drugs don't work, so now they're using AI to figure out what to do with them. PATHETIC!

0 · Reply

kebrik Aug. 4 at 1:35 PM

Today's movers: $LOBO, $ORIS, $MTVA, $OP, and $AACG

1 · Reply

SnakewithTits Aug. 4 at 1:24 PM

$MTVA Big news today — MetaVia teams up with Syntekabio to use AI for expanding DA-1241’s potential beyond MASH. Could open doors to new disease targets like type 2 diabetes. Stock still hovering near 52-week lows around $0.61, but long-term upside possible if AI results hit. Watching for volume and a bigger breakout from PM jump. 💵🐍

2 · Reply

StockDeni Aug. 4 at 12:57 PM

$MTVA good move by the company. It will run to 2 dollars or beyond. PROFIT.

0 · Reply

Thestocktraderhubzee Aug. 4 at 12:55 PM

$MTVA Metavia Announces A Research Collaboration With Syntekabio To Identify Additional Disease Targets And Optimize The Therapeutic Profile Of DA-1241, Metavia's Novel Oral G-Protein-Coupled Receptor 119 Agonist

0 · Reply

TA_Kongen Aug. 4 at 12:51 PM

$MTVA Private placement at .70. Will watch to see if big buyers start scooping shares at lower prices.

0 · Reply

2312132DD Aug. 4 at 12:49 PM

$MTVA FUCK

0 · Reply

dbr_island Aug. 4 at 12:48 PM

$MTVA there it goes VCIG is next Here’s why👇🚨🚨🚨

0 · Reply

Market Cap	16.43M
Revenue (ttm)	0.00
Net Income (ttm)	-27.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	21,975
Avg Vol	99,928
Day's Range	N/A - N/A
Shares Out	24.20M
Stochastic %K	71%
Beta	0.26
Analysts	Strong Sell
Price Target	$13.75